Brief: Kala Pharmaceuticals Reports Third Quarter Results

KALA BIO

08/11/2022 13:12

Nov 8 (Reuters) - Kala Pharmaceuticals Inc  KALA.O :
    * KALA PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
    * ENDED QUARTER WITH $52.4 MILLION IN CASH; SUFFICIENT FOR
FUNDING
OPERATIONS INTO 2Q 2024
    * KALA - PLANNING TO INITIATE PHASE 2/3 TRIAL OF KPI-012 FOR
PERSISTENT CORNEAL EPITHELIAL DEFECT (PCED) IN 4Q 2022; TOPLINE
DATA EXPECTED IN 1Q 2024
    * QTRLY NET INCOME PER SHARE ATTRIBUTABLE TO COMMON
STOCKHOLDERS—DILUTED $19.25
    * Q3 EARNINGS PER SHARE VIEW $10.75 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXNrPl4 
Further company coverage:  KALA.O 
 ((reuters.briefs@thomsonreuters.com;))